Researches and develops formulations of pre-approved therapeutic proteins and peptides. Focuses on treatments for diabetes and other metabolic diseases. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 48% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 61.9× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
The company sells $1.7M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $26.4M against $1.7M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.